Establishing a common language for the stakeholders in stratified medicine — including drug developers, diagnostic companies, regulators and payers — could help tackle the complex challenges posed by biomarker-based drug development.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Hughes, B. Developing tools for stratified medicine. Nat Rev Drug Discov 8, 919–920 (2009). https://doi.org/10.1038/nrd3070
Issue Date:
DOI: https://doi.org/10.1038/nrd3070
- Springer Nature Limited
This article is cited by
-
Quantifying factors for the success of stratified medicine
Nature Reviews Drug Discovery (2011)